专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022213360A1 SYNTHETIC LEATHER 审中-公开
公开(公告)号：WO2022213360A1
公开(公告)日：2022-10-13
申请号：PCT/CN2021/086151
申请日：2021-04-09
申请人： DOW GLOBAL TECHNOLOGIES LLC , YANG, Yunfeng , LIU, Xuejun , MADENJIAN, Lisa S. , PESEK, Stacy L. , YAN, Jinliang , MUNRO, Jeffrey C.
发明人： YANG, Yunfeng , LIU, Xuejun , MADENJIAN, Lisa S. , PESEK, Stacy L. , YAN, Jinliang , MUNRO, Jeffrey C.
IPC分类号： D06N3/04 , B32B27/32 , B32B27/12 , B32B5/18
摘要： The present disclosure provides an article. In an embodiment, the article includes (A) a top layer composed of a composition composed of (i) from 51 wt% to 90 wt% of a propylene-based polymer, and (ii) from 10 wt% to 49 wt% of an ethylene/octene multi-block copolymer having hard segments and soft segments. The ethylene/octene multi-block copolymer has a soft segment melt temperature (SS-Tm) less than 2℃. The article also includes (B) a bottom layer composed of a textile.

2. 发明申请

WO2008111082A1 PROCESS FOR THE SYNTHESIS OF IB-MECA 审中-公开
标题翻译：合成IB-MECA的方法
公开(公告)号：WO2008111082A1
公开(公告)日：2008-09-18
申请号：PCT/IL2008/000360
申请日：2008-03-13
申请人： CAN-FITE BIOPHARMA LTD. , BRUZINSKI, Paul , LIU, Xuejun , GIBB, Cameron , HERNANDEZ-ABAD, Pedro
发明人： BRUZINSKI, Paul , LIU, Xuejun , GIBB, Cameron , HERNANDEZ-ABAD, Pedro
IPC分类号： C07H19/16 , A61K31/7076 , A61P35/00
CPC分类号： C07H19/16 , C07H1/00 , Y02P20/55
摘要： The present disclosure provides a method for the synthesis of IB-MECA. More specifically, the present disclosure provides a simple and high yield method for Good Manufacturing Production (GMP) of IB-MECA. The method involves the reaction of 6-halopurine-9-riboside with a diol protecting reagent; oxidation of the primary alcohol in the diol protected 6-halopurine; reaction of the diol protected 6-halopurine with a nucleophile (e.g. methylamine); substitution of the halogen group with iodobenzylamine and removal of the diol protecting group.
摘要翻译：本公开提供了用于合成IB-MECA的方法。更具体地，本公开提供了IB-MECA的良好制造生产（GMP）的简单且高产率的方法。该方法涉及6-卤代嘌呤-9-核糖苷与二醇保护试剂的反应; 二醇中的伯醇的氧化被保护的6-卤代嘌呤; 二醇保护的6-卤代嘌呤与亲核试剂（如甲胺）的反应; 用碘苄胺取代卤素基团并除去二醇保护基团。

3. 发明申请

WO2022213359A1 SYNTHETIC LEATHER 审中-公开
公开(公告)号：WO2022213359A1
公开(公告)日：2022-10-13
申请号：PCT/CN2021/086150
申请日：2021-04-09
申请人： DOW GLOBAL TECHNOLOGIES LLC , YANG, Yunfeng , LIU, Xuejun , YANG, Hong , MADENJIAN, Lisa S.
发明人： YANG, Yunfeng , LIU, Xuejun , YANG, Hong , MADENJIAN, Lisa S.
IPC分类号： C08L23/10 , D06N3/00
摘要： An article is provided and includes (A) a top layer composed of a composition composed of (i) from 70 wt% to 88 wt% of an ethylene-based polymer, and (ii) from 12 wt% to 30 wt% of an oil, based on the total weight of the top layer. The article further includes (B) a bottom layer composed of a textile.

4. 发明申请

WO2005026381A2 MICROARRAY ANALYSIS OF HOST AND PATHOGEN GENE EXPRESSION CHANGES IN VIVO 审中-公开
标题翻译：病毒微生物分析和病原体基因表达变化
公开(公告)号：WO2005026381A2
公开(公告)日：2005-03-24
申请号：PCT/US2004/029886
申请日：2004-09-10
申请人： JANSSEN PHARMACEUTICA N.V. , LIU, Xuejun , MORROW, Brian, J. , MOTLEY, Stanley, Timothy , SHAW, Karen, Joy
发明人： LIU, Xuejun , MORROW, Brian, J. , MOTLEY, Stanley, Timothy , SHAW, Karen, Joy
IPC分类号： C12Q
CPC分类号： C12Q1/6834
摘要： Systems permitting simultaneous transcriptional analysis of the host and pathogen during an in vivo infection are described.
摘要翻译：描述了允许在体内感染期间同时转录宿主和病原体的系统的系统。

5. 发明申请

WO2021081982A1 OVERMOLDED TRANSPARENT STRUCTURE 审中-公开
公开(公告)号：WO2021081982A1
公开(公告)日：2021-05-06
申请号：PCT/CN2019/115013
申请日：2019-11-01
申请人： PERFORMANCE MATERIALS NA, INC. , LIU, Xuejun
发明人： LIU, Xuejun
IPC分类号： B44C5/00 , B44C5/06
摘要： A transparent injection overmolded structure (100) encapsulating a real botanical matter (70) including at least one first transparent multilayer film member (50), at least one second transparent multilayer film member (60), a real botanical matter (70) disposed and encapsulated between the surface of the first transparent multilayer film member (50) and the surface of the second transparent multilayer film member (60) forming an integral transparent multilayered encapsulation structure (30), a base member (40) for receiving and attaching to the transparent multilayered encapsulation structure (30), and an injection overmolded transparent plastic member (20) integral with and enveloping the base member (40) and the transparent multilayered encapsulation structure (30). Wherein the at least one first transparent multilayer film (50) member includes at least one low-seal initiation temperature inner layer (51) for contacting a botanical matter (70), at least one outer bonding layer (52) for contacting and bonding to an injection overmolded transparent plastic member (20), and at least one core barrier layer (53) interposed between the inner layer (51) and outer layer (52); wherein the at least one second transparent multilayer film member (60) includes at least one low-seal initiation temperature inner layer (61) for contacting a botanical matter (70), at least one outer bonding layer (62) for contacting and bonding to an injection overmolded transparent plastic member (20), and at least one core barrier layer (63) interposed between the inner layer (61) and outer layer (62). A process for producing the transparent injection overmolded structure (100) encapsulating a real botanical matter (70) is also disclosed.

6. 发明申请

WO2012031073A1 PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION 审中-公开
标题翻译：从相关的酮中制备出具有良好活性的去除的二级酒精的方法，而不会减少去除毒素
公开(公告)号：WO2012031073A1
公开(公告)日：2012-03-08
申请号：PCT/US2011/050139
申请日：2011-09-01
申请人： CONCERT PHARMACEUTICALS, INC. , KANAMARLAPUDI, Ramanaiah, C. , WEISSMAN, Steven, A. , EISENREICH, Emerich , LIU, Xuejun
发明人： KANAMARLAPUDI, Ramanaiah, C. , WEISSMAN, Steven, A. , EISENREICH, Emerich , LIU, Xuejun
IPC分类号： C07D473/10 , C07B59/00
CPC分类号： C12P17/182 , C07B59/002 , C07D473/10
摘要： The present invention provides a process for the preparation of enantiomerically enriched, deuterated secondary alcohols of Formula l-A by employing ketoreductases or carbonyl reductases without reducing deuterium incorporation.
摘要翻译：本发明提供了通过使用酮还原酶或羰基还原酶而不减少氘掺入来制备式I-A的对映体富集的氘代仲醇的方法。

7. 发明申请

WO2011037859A3 IDENTIFICATION OF ANTIGENIC PEPTIDES FROM MULTIPLE MYELOMA CELLS 审中-公开
标题翻译：从多种骨髓细胞中鉴定抗原肽
公开(公告)号：WO2011037859A3
公开(公告)日：2011-03-31
申请号：PCT/US2010/049466
申请日：2010-09-20
申请人： JANSSEN PHARMACEUTICA NV , ZELING, Cai , SHI, Wei-Xing , LIU, Xuejun, P. , WU, Jiejun
发明人： ZELING, Cai , SHI, Wei-Xing , LIU, Xuejun, P. , WU, Jiejun
IPC分类号： C07K7/00 , A61K39/00
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
摘要翻译：多发性骨髓瘤（MM）是克隆B细胞恶性肿瘤，并且通过传统的抗肿瘤治疗基本上不可治愈。 MM患者的中位生存期仅为3年。 MM的特征在于骨髓（BM）中成熟浆细胞的增殖和积累，导致骨破坏，骨髓衰竭，贫血和免疫功能降低。在多发性骨髓瘤细胞上呈递的MHC I类，HLA-A2相关肽的鉴定是开发MM的免疫疗法中的重要步骤。这里展示的是用于产生活化的T淋巴细胞的方法，所述活化的T淋巴细胞对装载肽的T2靶细胞和多发性骨髓瘤细胞系都是细胞毒性的。

8. 发明申请

WO2005026381A3 MICROARRAY ANALYSIS OF HOST AND PATHOGEN GENE EXPRESSION CHANGES IN VIVO 审中-公开
标题翻译：体内宿主及病原体基因表达变化的微阵列分析
公开(公告)号：WO2005026381A3
公开(公告)日：2005-11-24
申请号：PCT/US2004029886
申请日：2004-09-10
申请人： JANSSEN PHARMACEUTICA NV , LIU XUEJUN , MORROW BRIAN J , MOTLEY STANLEY TIMOTHY , SHAW KAREN JOY
发明人： LIU XUEJUN , MORROW BRIAN J , MOTLEY STANLEY TIMOTHY , SHAW KAREN JOY
IPC分类号： C12Q20060101 , C12Q1/68
CPC分类号： C12Q1/6834
摘要： Systems permitting simultaneous transcriptional analysis of the host and pathogen during an in vivo infection are described.
摘要翻译：描述了允许在体内感染期间同时转录分析宿主和病原体的系统。

9. 发明申请

WO2012031072A1 PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION 审中-公开
标题翻译：从相关的酮中制备出具有良好活性的去除的二级酒精的方法，而不会减少去除毒素
公开(公告)号：WO2012031072A1
公开(公告)日：2012-03-08
申请号：PCT/US2011/050138
申请日：2011-09-01
申请人： CONCERT PHARMACEUTICALS, INC. , KANAMARLAPUDI, Ramanaiah, C. , WEISSMAN, Steven, A. , EISENREICH, Emerich , LIU, Xuejun
发明人： KANAMARLAPUDI, Ramanaiah, C. , WEISSMAN, Steven, A. , EISENREICH, Emerich , LIU, Xuejun
IPC分类号： C07B59/00 , C07D473/04 , C12P17/18
CPC分类号： C12P17/182 , C07B59/002 , C07D473/04 , C12Y101/01184
摘要： The present invention provides a convenient and efficient process for the preparation of enantiomerically enriched, deuterated secondary alcohols without reducing deuterium incorporation.
摘要翻译：本发明提供了用于制备对映体富集的氘化仲醇而不减少氘掺入的方便和有效的方法。

10. 发明申请

WO2011037859A2 IDENTIFICATION OF ANTIGENIC PEPTIDES FROM MULTIPLE MYELOMA CELLS 审中-公开
标题翻译：从多种MYELOMA细胞鉴定抗原肽
公开(公告)号：WO2011037859A2
公开(公告)日：2011-03-31
申请号：PCT/US2010049466
申请日：2010-09-20
申请人： JANSSEN PHARMACEUTICA NV , ZELING CAI , SHI WEI-XING , LIU XUEJUN P , WU JIEJUN
发明人： ZELING CAI , SHI WEI-XING , LIU XUEJUN P , WU JIEJUN
IPC分类号： A61K38/20 , A61K38/08 , A61K38/10 , C07K7/06 , C07K7/08
CPC分类号： C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K7/06 , C07K14/4748 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/58 , C12N2501/599 , C12N2502/50 , C12N2502/99
摘要： Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.
摘要翻译：多发性骨髓瘤（MM）是一种克隆性B细胞恶性肿瘤，通过常规的抗肿瘤治疗基本上无法治愈。 MM患者的中位生存期仅为3年。 MM的特征在于骨髓（BM）中成熟浆细胞的增殖和积累导致骨破坏，BM衰竭，贫血和免疫功能降低。在多发性骨髓瘤细胞上呈现MHC I类HLA-A2，相关肽的鉴定是开发MM免疫疗法的重要一步。这里提出的是产生对加载肽的T2靶细胞和多发性骨髓瘤细胞系具有细胞毒性的活化的T淋巴细胞的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式